Nanomerics is a privately held speciality pharmaceutics company based in London, UK.
Nanomerics is focused on the development of better medicines - rather than better drugs - reducing the typical development costs, resources and timelines.
​
Nanomerics has a pipeline of its own as well as partnered programs addressing important areas of medical need, including non-addictive pain therapies and degenerative CNS conditions, therapies to preserve eye sight, or medicines where tablets replace intravenous administrations or applications that minimise the risk of viral infections, e.g. from Sars-Cov2.
Who we are.
Nanomerics develops precision medicines that address medical need by focusing on reducing the typical development costs, resources and timelines.
​
Nanomerics' proprietary technology addresses medical and non-medical applications with a focus on conditions at the front and back of the eye, CNS conditions and challenging oral active pharmaceutical ingredients (APIs).
​
Nanomerics has a pipeline of its own as well as partnered programs addressing important areas of medical need and orphan indications.
Precision Medicines
What we do.
Nanomerics' creates better medicines by enhancing and repurposing existing drugs (and new chemical entities - NCEs) using its proprietary platform technologies.
​
Nanomerics has a pipeline of its own as well as partnered programs addressing important areas of medical need. These include, for example, non-addictive pain therapies and degenerative CNS conditions, therapies to treat eye conditions and preserve eye sight in orphan diseases, or medicines where tablets replace intravenous administrations.
There are also non-medical applications such as Nanomerics' Molecular Masks, a nasal spray that minimise the risk of viral infections, e.g. from Sars-Cov-2.
How we do it.
Nanomerics is a world leader in molecular engineered materials (MEM). These are used to create platforms that enhance known and novel drugs and active compounds to address a range of different applications, including the development of new medicines.
​
Applied to the engineering of biocompatible polymers, this allows the formation of tailored supramolecular assemblies. These building blocks can then be used for advanced drug delivery or biomaterials.
​
One example of this approach is Nanomerics' Molecular Envelope Technology (MET) platform. The association of drugs with the MET platform dramatically improves their delivery. Getting more drug to the site of action over prolonged periods of time results in improved medicines with better activity and reduced side effects.